Research Groups

Research Groups

Kaan Boztug Group

Immune Deficiency, Cancer Predisposition & Precision Oncology
Our group works at the interface of  inborn immune disorders and inherited predisposition to childhood tumors, aiming  to understand fundamental mechanisms of immune surveillance relevant to pediatric oncology and immunotherapy approaches.

Martin Distel Group

Innovative Cancer Models
Our research focus is on the generation of pediatric cancer models in zebrafish to better understand tumor initiation and tumor progression on a cellular and molecular level. In addition, zebrafish disease models are applied in small compound screens to identify therapeutic compounds.

Michael Dworzak Group

Immunological Diagnostics
We aim at developing and evaluating new diagnostic, prognostic and therapeutic approaches for paediatric leukaemias using high-end multi-colour flow cytometry.

René Geyeregger Group

Clinical Cell Biology and FACS Core Unit
With our engagement in flow cytometry and GMP-compliant work, we are a supportive interface between research and therapy.

Oskar Haas Group

Clinical Genetics
Leukaemias are malignant diseases of the haematopoietic system that are caused by genetic defects. Our primary task is to diagnose and in detail characterise these diverse changes which are important for specific treatment and basic research, with the use of molecular and cytogenetic methods.

Florian Halbritter Group

Integrative Analysis & Developmental Cancer Genomics
We combine "multi-omics" analysis with computational, statistical, and machine learning methods to dissect the molecular framework of pediatric cancers.

Caroline Hutter Group

LCH Biology
The goal of our laboratory is to better understand the pathobiology of Langerhans Cell Histiocytosis (LCH) in order to develop new treatment approaches to the disease.

Eva König Group

Tumour Immunoediting
We study the role of NK cells in tumor immunoediting and aim to identify the molecular mechanisms of tumor immune evasion.

Heinrich Kovar Group

Molecular Biology of Solid Tumours
To increase therapeutic efficacy while decreasing side effects, we have to specifically target the Achille`s heel of the disease.

Ruth Ladenstein Group

Studies & Statistics for Integrated Research and Projects
Multinational networking is fundamental for clinical research of malignant cancer in children and adolescents. Only controlled large-scale clinical trials allow improving complex treatment strategies, whilst smaller studies allow testing innovative drug medications to further improve survival rates. The clinical trail unit S2IRP undertakes all efforts to serve the complex tasks of clinical trial management.

Thomas Lion Group

Molecular Microbiology
Our group primarily focuses on the improvement of treatment outcomes, particularly in transplant recipients and patients with life-threatening infections, by developing and implementing new diagnostic technologies.

Davide Seruggia Group

Pediatric Leukemia Biology

We study non-coding regulatory elements, chromatin modifiers and other epigenetic factors in the context of leukemia and other pediatric malignancies.

Sabine Strehl Group

Genetics of Leukaemias
Tracking down the faulty genes that cause leukamia with the ultimate goal to establish predictive biomarkers for the optimisation of risk-adapted therapy.

Sabine Taschner-Mandl Group

Tumour Biology
We aim to establish, validate and apply new diagnostic and therapeutic tools to facilitate personalized treatment of children with malignant tumors.

Eleni Tomazou Group

Epigenome-based Precision Medicine
The aim of our group is to establish an epigenome-based precision medicine program for pediatric sarcomas.

Christian Doppler Laboratory for Next Generation CAR T Cells

Head: Dr. Manfred Lehner (PhD)
Our CD - laboratory focuses on the development of therapeutic strategies based on T cells modified with chimeric antigen receptors (CARs).

Studies & Statistics for Integrated Research and Projects

Head: Ruth Ladenstein
Multinational networking is fundamental for clinical research of malignant cancer in children and adolescents. Only controlled large-scale clinical trials allow improving complex treatment strategies, whilst smaller studies allow testing innovative drug medications to further improve survival rates. The clinical trail unit S2IRP undertakes all efforts to serve the complex tasks of clinical trial management.